The burden of metastatic melanoma: Treatment patterns, healthcare use (utilization), and costs

Melanoma Research

Volumn 23, Issue 2, 2013, Pages 159-166

  Reyes, Carolina ^b   Dacosta Byfield, Stacey ^a   Linke, Rolf ^b   Satram Hoang, Sacha ^c   Teitelbaum, April H ^a  

^a OPTUM   (United States)

^b GENENTECH INC   (United States)

^c QD Research Inc   (United States)

Author keywords

healthcare cost; metastatic melanoma; survival; treatment; utilization

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; INTERLEUKIN 2; PACLITAXEL; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHARLSON COMORBIDITY INDEX; CHILD; DISTANT METASTASIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFANT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MORTALITY; NEWBORN; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84874946247     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835e58d6     Document Type: Article

References (20)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687-701.
2. The American Cancer Society. Available at: http://nci.nih.gov/aboutnci/ servingpeople/snapshots/melanoma.pdf [Accessed 19 December 2012].
3. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109:455-464.
4. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93:678-683.
5. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9:587-595.
6. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC,Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
9. Wolchok J, Thomas L, Bondarenko L. Integration of ipilimumab in the first-line setting improves survival for patients with metastatic melanoma. 2011 ASCO Annual Meeting, Chicago, IL, USA. 6 March 2011.
10. Chapman PB, Hauschild A, Robert C. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine in patients with V600E BRAF-mutated melanoma. 2011 ASCO Annual Meeting, Chicago, IL, USA. 6 March 2011.
11. National Institutes of Health. NIH News. New method of gene therapy alters immune cells for treatment of advanced melanoma; technique may also apply to other common cancers. Available at: http://www.nih.gov/news/pr/aug2006/nci- 31b.htm [Accessed 22 October 2012].
12. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 1998; 38 (Pt 1):669-680.
13. Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy 2009; 7:31-41.
14. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress, 2009. Available at: http://www.cms.hhs.gov/ HIPAAGenInfo/Downloads/HIPAALaw.pdf [Accessed 17 June 2011].
15. US Department of Bureau of Labor Statistics. Consumer price index. Chained consumer price index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics; 2008. Available at: http://data.bls.gov/cgi-bin/ surveymost?su.
16. Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online.J 2009; 15:1.
17. Tu TJ, Ma MW, Monni S, Rose AE, Yee H, Darvishian F, et al. A high proliferative index of recurrent melanoma is associated with worse survival. Oncology 2011; 80:181-187.
18. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Arch Dermatol 2010; 146:249-256.
19. National Comprehensive Cancer Network. NCCN guidelines. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp [Accessed 22 October 2012].
20. Dickson R, Boland A, Bagust A, Blundell M, Massey G, Dundar Y, et al. Ipilimumab for previously treated unresectable malignant melanoma: a single technology appraisal. Report commissioned by the NIHR HTA Programme as project 08/209/01. Liverpool, UK: LRiG, The University of Liverpool; 2011.